IONIS PHARMACEUTICALS INC 8-K

What Happened
Ionis Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2026 in a press release issued April 29, 2026 and filed on Form 8‑K (Item 2.02). In addition to GAAP results, the company presented pro forma (non‑GAAP) results that exclude non‑cash compensation expense related to equity awards and the related tax effects.

Key Details

• Press release announcing quarterly results was issued April 29, 2026 and furnished as an exhibit to the 8‑K.
• The results cover the quarter ended March 31, 2026 (Q1 2026).
• Non‑GAAP adjustments remove non‑cash equity‑based compensation expense and the associated tax effects.
• The company states the pro forma presentation is intended to help users assess historical performance and project future operating results and cash flows.

Why It Matters
For investors, the filing signals Ionis’ quarterly earnings and revenue information is available and that the company is providing both GAAP and adjusted views of performance. The non‑GAAP figures will show operating results with equity‑based, non‑cash compensation removed, which can materially change margins and profitability metrics used by analysts and retail investors. Review the company’s press release and accompanying filings for the specific revenue, income and cash‑flow figures.